The current financial score of Procept Biorobotics Corp is 7.76. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 94.50M, representing a year-over-year increase of 19.34%, while its net profit experienced a year-over-year increase of 37.20%.
The current valuation score of Procept Biorobotics Corp is 8.22. Its current P/E ratio is -9.88, which is -7.74% below the recent high of -9.12 and -416.17% above the recent low of -51.02.
The current earnings forecast score of Procept Biorobotics Corp is 6.67. The average price target is 24.23, with a high of 51.00 and a low of 16.00.
The current price momentum score of Procept Biorobotics Corp is 4.09. Currently, the stock price is trading between the resistance level at 21.30 and the support level at 16.41, making it suitable for range-bound swing trading.
The current institutional shareholding score of Procept Biorobotics Corp is 10.00. The latest institutional shareholding proportion is 114.22%, representing a quarter-over-quarter increase of 6.52%. The largest institutional shareholder is Baillie Gifford, holding a total of 911.75K shares, representing 0.02% of shares outstanding, with 17.74% decrease in holdings.
The current risk assessment score of Procept Biorobotics Corp is 5.44. The company's beta value is 0.85. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.